Oxford Global are delighted to present the highly anticipated 2nd Annual Genome Editing Congress, taking place on 10 – 11 November 2016, London, UK. This unique event will feature presentations covering advances in genome editing techniques as well as therapeutic applications case studies of genome editing.
To download the agenda, please click here: http://www.genomeediting-congress.com/download-agenda
This congress will have 2 interactive streams:
Co-located with Europe’s well-established 8th Annual Next Generation Sequencing Congress and 4th Annual Single Cell Analysis Congress, the event will bring together over 450 senior level delegates from prestigious academic & research institutions as well as representatives from pharmaceutical companies.
The genome editing market represents a rapidly evolving area of pharmaceutical research since the discovery of the CRISPR/Cas systems that have revolutionised biological research. Significant advancements have been made in the fields of improving genome editing tools & technologies, gene delivery systems and utilising genome editing for therapeutic applications.
Key presentations will include therapeutic genome editing with CRISPR presented by Pentao Liu, Senior Group Leader, Wellcome Trust Sanger Institute and utilising genome editing in drug discovery & development addressed by Barry Rosen, VP and Senior Principal Scientist, AstraZeneca.
For the latest conference updates follow us on Twitter @xgenseq and join the event conversation on #xgenseq16.
For more details on how to register for the meeting contact Danielle Dalby on firstname.lastname@example.org or call +44(0)1865 248455.